Bilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer
Brita Arver(Karolinska University Hospital), Kerstin Sandelin(Karolinska Institutet), Hans Ehrencrona(Lund University), Leif Bergkvist(Västerås Municipality), Annika Baan(Sahlgrenska University Hospital), Monica Emanuelsson, Karin Isaksson(Karolinska Institutet), Marie Wickman(Sophiahemmet University College), Hans Atterhem(Umeå University), Henrik Hellborg(Karolinska Institutet), Anita Ringberg(Uppsala University), Per Karlsson(University of Gothenburg), Jonas Lundberg(Uppsala University Hospital), Karin Henriksson(Uppsala University Hospital), Yvonne Brandberg(Karolinska Institutet), Niklas Loman(Lund University), Marie Stenmark Askmalm(Linköping University)
Cited by 61
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k